|
|
Post by sayhey24 on Mar 8, 2024 14:01:07 GMT -5
Maybe what we should do is meet up in Danbury on ASM day and if they don't let us in we can sit in the parking lot and we all bring a bottle of our favorite whiskey. I am not really a rye guy or scotch but as I said I am not turning much down for free. As a MNKD investor quantity is key. I have a pop up tent and tables/chairs I can throw in my truck. Then we can take some pictures and send them to Mike wishing he was "here". I can even bring my faded cooler and old afresa t-shirt. Tailgate! What, you want me to bring the cornhole and horseshoes too? I guess I could bring a grill too but if they let us in there is a nice cafeteria and we could order in hoagies. |
|
|
|
Post by ktim on Mar 8, 2024 14:12:37 GMT -5
Hence why I don't find a graph only showing 2 hours very interesting... doesn't at all give the full picture of Afrezza vs RAA pk/pd difference.
|
|
|
|
Post by prcgorman2 on Mar 8, 2024 14:13:46 GMT -5
What, you want me to bring the cornhole and horseshoes too? I guess I could bring a grill too but if they let us in there is a nice cafeteria and we could order in hoagies. Love me some tailgate BBQ with beer. Not sure how many employees are in Danbury, but we could learn a lot and show some genuine appreciation for all their hard work. |
|
|
|
Post by liane on Mar 8, 2024 14:43:52 GMT -5
Sayhey I suggest you try out New Riff distillery’s single barrel selections of rye and bourbon. Much higher price point than Evan but if we keep seeing this MNKD momentum it won’t be an issue 😀 Maybe what we should do is meet up in Danbury on ASM day and if they don't let us in we can sit in the parking lot and we all bring a bottle of our favorite whiskey. I am not really a rye guy or scotch but as I said I am not turning much down for free. As a MNKD investor quantity is key. I have a pop up tent and tables/chairs I can throw in my truck. Then we can take some pictures and send them to Mike wishing he was "here". I can even bring my faded cooler and old afresa t-shirt. I'll wear my MNKD ballcap. |
|
|
|
Post by agedhippie on Mar 8, 2024 15:41:22 GMT -5
Hence why I don't find a graph only showing 2 hours very interesting... doesn't at all give the full picture of Afrezza vs RAA pk/pd difference. That data is already well known, it's essentially the same as was presented last year just with more people. ATTD 2023 The first question that will be asked is what happens after the two hour mark. I suspect that was asked in the room and I would love to have heard the answer because it's the make or break question. If you have to dose twice as often with Afrezza it's going to be a problem for most people (Type 1). What mattered here was less the presentation, which was the same, but more that Irl Hirsch was putting his name behind it. |
|
|
|
Post by agedhippie on Mar 8, 2024 15:58:18 GMT -5
More aggressive dosing of the RAA? At the Adcom I heard the FDA say that to that doctor who got great results in the 171 when he had his patients follow-up dose. She accused him of cheating and when she asked him why he didn't do that with the RAA arm he looked at her and said "I would have killed my patients". That lady was mad. Soon after they took a break and she was in the hallway fuming. ... In the UK NHS at that time would not allow you to go onto MDI unless you used corrections. The US lagged the rest of the world on that. Of course you should use follow-up doses. Likewise it's fine to do the same with RAA provided you account for insulin onboard (pumps do that automatically for you.) |
|
|
|
Post by sayhey24 on Mar 8, 2024 16:24:55 GMT -5
More aggressive dosing of the RAA? At the Adcom I heard the FDA say that to that doctor who got great results in the 171 when he had his patients follow-up dose. She accused him of cheating and when she asked him why he didn't do that with the RAA arm he looked at her and said "I would have killed my patients". That lady was mad. Soon after they took a break and she was in the hallway fuming. ... In the UK NHS at that time would not allow you to go onto MDI unless you used corrections. The US lagged the rest of the world on that. Of course you should use follow-up doses. Likewise it's fine to do the same with RAA provided you account for insulin onboard (pumps do that automatically for you.) Lets just use the afrezza and stop trying to use the RAA for what it is not good for. They are too damn slow. Do you see Ginger V. double dosing her RAA? She will use it when she wants the tail. Didn't we learn anything from Irl's presentation today? Of course to use the afrezza the PWDs needs to be able to get it and get it at an affordable price. The Inhale-3 target users hit that current sweet stop for afrezza insurance access. |
|
|
|
Post by sayhey24 on Mar 8, 2024 16:28:26 GMT -5
Hence why I don't find a graph only showing 2 hours very interesting... doesn't at all give the full picture of Afrezza vs RAA pk/pd difference. That data is already well known, it's essentially the same as was presented last year just with more people. ATTD 2023The first question that will be asked is what happens after the two hour mark. I suspect that was asked in the room and I would love to have heard the answer because it's the make or break question. If you have to dose twice as often with Afrezza it's going to be a problem for most people (Type 1). What mattered here was less the presentation, which was the same, but more that Irl Hirsch was putting his name behind it. The answer is if you are in TITR do nothing. If you are rising and going out of TITR take another puff. Ginger V. has a nice video on this. Personally, I would rather watch her video's than watch Irl's but thats me. I think in the video Ginger says double dosing is no problem. She sees afrezza as a blanket. I guess they will also pole these study participants but I have never really heard anyone complain of a second puff. At first they are more concerned it will make them go low. The real issue will be cost for second dosing and correction dosing for snack, etc. |
|
|
|
Post by akemp3000 on Mar 8, 2024 17:38:04 GMT -5
Isn't the primary takeaway from this presentation that a highly reputable industry authority (versus in-house company scientist) at a global conference, has announced there will be less hypos versus the current SOC when using Afrezza? Secondly, it's to be noted that industry influencers at all the participating test sites, including the Mayo Clinic, will now be discussing the excellent results? Just wanting to understand why some are insinuating this is not a big deal. The market has reacted nicely.
|
|
|
|
Post by agedhippie on Mar 8, 2024 18:18:40 GMT -5
Isn't the primary takeaway from this presentation that a highly reputable industry authority (versus in-house company scientist) at a global conference, has announced there will be less hypos versus the current SOC when using Afrezza? Secondly, it's to be noted that industry influencers at all the participating test sites, including the Mayo Clinic, will now be discussing the excellent results? Just wanting to understand why some are insinuating this is not a big deal. The market has reacted nicely. Yes, that is my point. Having Irl Hirsch repeating last years numbers matters because of who he is. That is the win in this. The results in and of themselves are not going to move endos. I would love to know what else he said. |
|
|
|
Post by sayhey24 on Mar 8, 2024 18:22:44 GMT -5
Isn't the primary takeaway from this presentation that a highly reputable industry authority (versus in-house company scientist) at a global conference, has announced there will be less hypos versus the current SOC when using Afrezza? Secondly, it's to be noted that industry influencers at all the participating test sites, including the Mayo Clinic, will now be discussing the excellent results? Just wanting to understand why some are insinuating this is not a big deal. The market has reacted nicely. Of course it is and the potential for better TITR. Inhale-3 is a great study and we have a top KOL as the study chair and as today's presenter. As our president would say "Joey - this is a BIG F'ing deal". |
|
|
|
Post by agedhippie on Mar 8, 2024 18:44:00 GMT -5
Lets just use the afrezza and stop trying to use the RAA for what it is not good for. They are too damn slow. Do you see Ginger V. double dosing her RAA? She will use it when she wants the tail. Didn't we learn anything from Irl's presentation today? ... TBH I don't really pay attention to what other diabetics do, and that is true for a lot of the diabetics I know. You rapidly learn that there is an army of people out there that thinks their way is the one true light, and while that may be true for them it really isn't for you. Ginger is a good example. Afrezza works for her, but she had a sub-6.0 hBA1c with RAA even before Afrezza - that is way more work than I am prepared to even think about! My life is nothing like hers so I wish her luck and carry on my own path. |
|
|
|
Post by longliner on Mar 8, 2024 18:49:55 GMT -5
Lets just use the afrezza and stop trying to use the RAA for what it is not good for. They are too damn slow. Do you see Ginger V. double dosing her RAA? She will use it when she wants the tail. Didn't we learn anything from Irl's presentation today? ... TBH I don't really pay attention to what other diabetics do, and that is true for a lot of the diabetics I know. You rapidly learn that there is an army of people out there that thinks their way is the one true light, and while that may be true for them it really isn't for you. Ginger is a good example. Afrezza works for her, but she had a sub-6.0 hBA1c with RAA even before Afrezza - that is way more work than I am prepared to even think about! My life is nothing like hers so I wish her luck and carry on my own path.Fortunately for MNKD and Afrezza, your experience is anecdotal. The studies are adding up. Millions of very lucky children are on the horizon for Afrezza. |
|
|
|
Post by ktim on Mar 8, 2024 19:38:05 GMT -5
Isn't the primary takeaway from this presentation that a highly reputable industry authority (versus in-house company scientist) at a global conference, has announced there will be less hypos versus the current SOC when using Afrezza? Secondly, it's to be noted that industry influencers at all the participating test sites, including the Mayo Clinic, will now be discussing the excellent results? Just wanting to understand why some are insinuating this is not a big deal. The market has reacted nicely. Who was insinuating? I know I was stating that I didn't think it was a big deal... no insinuation. I don't really do insinuation. Was there someone else insinuating? Of course I will admit I didn't know the guy presenting from Casper the Ghost, so I was not factoring in any wow factor that may entail. I hope that is something special that will move the needle with regard to institutional investors and/or doctors. |
|
|
|
Post by agedhippie on Mar 9, 2024 3:36:21 GMT -5
Fortunately for MNKD and Afrezza, your experience is anecdotal. The studies are adding up. Millions of very lucky children are on the horizon for Afrezza. Indeed. My experience, Ginger's experience, and the experiences of the other diabetics I know are all anecdotal and why we have trials. Studies are interesting in so far as they suggest ideas for proper trials such as INHALE-1 and INHALE-3. |
|
